Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Dalton Transactions (Cambridge, England : 2003)|December 8, 2025
Palladium(0) and Juglone: a new alliance in the fight against ovarian cancerGiovanni Tonon, Anna Rafaniello, Matteo Mauceri, et al.Nanoscale|August 7, 2026
Atomically precise gold nanoclusters stabilized by neutral ligands as active anticancer agentsGiulia Saggiotti, Matteo Mauceri, Matteo Bevilacqua, et al.Molecules (Basel, Switzerland)|January 23, 2024
Rational Design of Palladium(II) Indenyl and Allyl Complexes Bearing Phosphine and Isocyanide Ancillary Ligands with Promising Antitumor ActivityEnrica Bortolamiol, Eleonora Botter, Enrico Cavarzerani, et al.Toxics|February 24, 2022
Early Warnings by Liver Organoids on Short- and Long-Chain PFAS ToxicityStefano Palazzolo, Isabella Caligiuri, Andrea Augusto Sfriso, et al.ACS Omega|November 8, 2021
Self-Therapeutic Cobalt Hydroxide Nanosheets (Co(OH)2 NS) for Ovarian Cancer TherapyMuhammad Adeel, Salvatore Parisi, Matteo Mauceri, et al.Dalton Transactions (Cambridge, England : 2003)|September 10, 2021
Dinuclear gold(I) complexes with N-phosphanyl, N-heterocyclic carbene ligands: synthetic strategies, luminescence properties and anticancer activityGianmarco Trevisan, Valentina Vitali, Cristina Tubaro, et al.Journal of Enzyme Inhibition and Medicinal Chemistry|December 13, 2021
New PIN1 inhibitors identified through a pharmacophore-driven, hierarchical consensus docking strategyGiulio Poli, Miriana Di Stefano, Joan Arias Estevez, et al.Journal of Medicinal Chemistry|August 9, 2024
Palladium(II)-Indenyl Complexes Bearing N-Heterocyclic Carbene (NHC) Ligands as Potent and Selective Metallodrugs toward High-Grade Serous Ovarian Cancer ModelsEnrica Bortolamiol, Matteo Mauceri, Rachele Piccolo, et al.Dalton Transactions (Cambridge, England : 2003)|April 30, 2024
Unveiling the promising anticancer activity of palladium(II)-aryl complexes bearing diphosphine ligands: a structure-activity relationship analysisGiovanni Tonon, Matteo Mauceri, Enrico Cavarzerani, et al.Cancer Letters|November 15, 2025
Nanoformulation of a Pin1 inhibitor potentiates the efficacy of liposomal doxorubicin in second-line therapy for ovarian cancerGloria Saorin, Matteo Mauceri, Isabella Caligiuri, et al.Pageof 2